A Study to Evaluate Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390g
Status:
Completed
Trial end date:
2003-04-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter study designed to evaluate the efficacy and safety of
efalizumab administered at weekly SC (subcutaneous) doses of 1.0 mg/kg followed by efalizumab
taper in subjects with plaque psoriasis who previously participated in Study ACD2390g.